Back to Ovarian Cancer
This trial is complete. It is no longer accepting participants. Results may be available on ClinicalTrials.gov.

NCT03378297

NCT03378297
Completed Early Phase 1

Who may be able to join

Who might be able to join this trial:

  • You have been diagnosed with advanced ovarian cancer, fallopian tube cancer, or primary peritoneal cancer (at least stage 3).
  • You are 18 years of age or older.
  • You have not previously received any treatment for gynaecological cancer (women previously treated for cervical cancer or pre-cancerous changes on the cervix may still qualify if that treatment finished at least one year before your current diagnosis).
  • Your blood test results meet certain minimum health levels, including acceptable counts for white blood cells, platelets, haemoglobin, kidney function, liver function, blood sugar (HbA1c), and blood clotting — all tested within 14 days before starting the study drug.
  • You are able to read and understand a consent form and are willing to sign it.
  • You have suitable veins for the blood samples required by the study.

Who may not be able to join:

  • You are unable to understand the study information or give your consent due to language barriers, mental capacity, or your illness.
  • You are unable to swallow or take medication by mouth.
  • You are currently pregnant.
  • You have had a previous allergic reaction to a drug with a similar composition to the study drug (confirm with trial site).
  • You have a history of blood clotting problems or a known bleeding disorder.
  • You are known to be hepatitis B surface antigen positive, have HIV, or have or are suspected to have an active hepatitis C infection.
  • You have been diagnosed with or treated for another cancer within the last year, or you have a previous cancer that has not been fully cleared — except for certain skin cancers or fully removed non-invasive cancers.
  • You are currently taking part in, or have taken part in, another clinical study involving medication within the last four weeks.
  • You have an immune deficiency disorder, or have received immune-suppressing medication within the last 7 days (low-dose corticosteroids may be acceptable — confirm with trial site).
  • Your cancer type has been confirmed by biopsy to be something other than high-grade serous ovarian cancer.
  • You have active cancer spread to the brain or the lining around the brain.
  • You currently have an active infection that requires treatment.
  • You currently have a bowel blockage (obstruction).
  • You have certain serious health conditions, including severe kidney failure (stage 4 or above), significant heart failure (NYHA grade III or above), a history of severe psychiatric illness, or a current diagnosis of alcoholism or drug addiction.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

Early Phase 1: approximately ~10% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.

Trial details

Status
Completed
Phase
Early Phase 1
Sponsor
Haukeland University Hospital
Registry
clinicaltrials_gov
Start date
4 May 2018
Est. completion
5 January 2023

Where this trial is recruiting

🇳🇴 Norway

Primary endpoints

Changes in the expression of biomarkers

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 30 June 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

View original record on ClinicalTrials.gov